

# ENS-CCA / Precision-BTC Network Joint Meeting

June 11-12, 2026

**Conference Directors** Luke Boulter / Rocio Macias / Chiara Braconi

**Local Organizer** Konstantinos Athanasopoulos

Day 1	Academia-Pharma Interaction		June 11th 2026
TIME (CEST)	TITLE	SPEAKER	
8:00-8:45	Registration, badge & material delivery		
8:45-9:00	Welcome words	Konstantinos Athanasopoulos (GR)	
9:00 - 9:20	ENSCCA 10 Years Reflection	Luke Boulter (UK)	
9:20 - 9:30	COST Update/Overview	Rocio Macias (Spain)	
<b>9:30 - 10:45 SESSION 1: TRANSLATION INTO CLINICAL DEVELOPMENT: ROLE OF AI IN BIOMARKERS &amp; DIAGNOSTICS</b>			
<i>Moderators:</i>		<i>Alejandro Forner (Spain) &amp; Tim Kendall (UK)</i>	
9:30 - 9:40	Challenges in diagnostics of Biliary Tract Cancers	Pedro Rodrigues (Spain)	
9:40 - 10:00	Panel discussion	<i>With the addition of:</i> Jesus Banales (Spain), Stephen Rossi (Spain), Martine Walmsley (UK)	
<i>Moderators:</i>		<i>Anna Saborowski (Germany) &amp; Victor Moreno (Spain)</i>	
10:00 - 10:10	Diagnostics: the challenges of bringing a new biomarker to clinical practice	Alisa Stumm (Boehringer Ingelheim)	
10:10 - 10:20	Example of a biomarker-driven therapeutics: what is the challenge and how can academia help?	Servier Speaker	
10:20 - 10:45	Panel discussion	<i>With the addition of:</i> Stacie Lindsey (USA), Benjamin Goeppert (Germany)	
<b>10:45 - 11:30 Coffee Break</b>			
<b>11:30-13:00 SESSION 2: PATIENT INVOLVEMENT INTO EARLY TRIALS</b>			
<i>Moderators:</i>		<i>Angela Lamarca (Spain) &amp; John Bridgewater (UK)</i>	
11:30-11:40	Challenges of rare cancers in clinical trials	Arndt Vogel (Germany)	
11:40-11:50	Challenges of rare cancers in clinical trials	Jazz Pharmaceuticals	
11:50-12:00	Phase I trials - Patient views: how can patient advocacy groups impact on trial design?	Juan Valle (USA)	
12:10-12:20	IDH success trial phase 1: how did it develop?	Lorenza Rimassa (ILCA member, Italy)	
12:20-12:30	How to make academic trials with on-patent drugs successful	John Bridgewater (UK)	
12:30 - 13:00	Panel discussion	<i>With the addition of:</i> Paul Howard (AMMF), Matteo Fassan (Italy)	
<b>13:00 - 14:30 Lunch Break</b>			
<b>14:30 - 15:30 Oral Abstracts</b>			
<i>Moderators:</i>		<i>Rui Castro (Portugal) &amp; Mairead McNamara (UK)</i>	
<b>15:30 - 16:15 KEYNOTE TALK</b>			
Introduction		Chiara Braconi (UK)	
Therapeutic development: directions from basic research		Tim Greten (USA)	
<b>16:15 - 17:35 SESSION 3: DRUG DEVELOPMENT: NEW TARGETS &amp; COMPOUNDS TO CLINIC</b>			
<i>Moderators:</i>		<i>Teresa Macarulla (Spain) &amp; Tim Greten (USA)</i>	
16:15-16:25	Approach from Big Pharma: what are you looking for when you invest in a new compound?	Simon Hollingsworth (AstraZeneca)	
16:25-16:35	Approach from Smaller Biotech: the evolution from academia to industry	Flavia Scialpi (Trogenix, UK)	
16:35-16:45	ADCs: where are we going?	Victor Moreno (Spain)	
16:45-16:55	Drug development in a patients' niche: how to collaborate between industry and academia?	Kristin Ryan (Eleva Therapeutics, USA)	
16:55-17:05	Supporting devices for drug discovery	Ana Lleo (Italy)	
17:05 - 17:35	Panel Discussion	<i>With the addition of:</i> Tian Tian (Spain)	
<b>17:35 - 18:30 Poster Tour</b>			
<i>Moderators:</i>		<i>Konstantinos Athanasopoulos (Greece), Pilar Acedo (UK) &amp; Jerzy Kotlinowski (Poland)</i>	
<b>20:30 Joint Dinner</b>			

Day 2	Precision-BTC Network Annual Conference		June 12th 2026
TIME	TITLE	SPEAKER	
8:00 - 8:30	Registration, badge & material delivery		
<b>SESSION 1: WG1 - Identification of epidemiological heterogeneity in Europe</b>			
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Marcin Krawczyk (Poland) &amp; TBD</i>	
8:30 - 8:45	Stromal drivers of metastatic niche formation in cholangiocarcinoma	Veronika Lukacs-Kornek (Germany)	
8:45 - 9:00	Genome-wide methylation profiling from BTCs and PSC using blood DNA provides diagnostic, prognostic tools and biological insights	Ghada Nouairia (Sweden)	
9:00 - 9:15	A machine learning-powered tool to characterize CCA prognosis	Lorenzo Manganaro (Italy)	
9:15 - 9:30	Personalize prevention for CCA in PSC patients	Shahid Khan (UK)	
<b>09:30 - 10:30 SESSION 2: WG2 - Personalised early detection of BTC</b>			
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Guido Carpino (Italy) &amp; Stephanie Roessler (Germany)</i>	
9:30 - 9:45	Molecular diagnostic solutions for detection of malignant biliary strictures	Michael Dill (Germany)	
9:45 - 10:00	Novel blood metabolomic tests for the diagnosis of primary sclerosing cholangitis and associated cholangio	Ainhoa Lapitz (Spain)	
10:00 - 10:15	TBD	TBD	
10:15 - 10:30	TBD	TBD	
<b>10:30-11:00 Coffee Break &amp; Group Photo</b>			
<b>11:00 - 12:00 SESSION 3: WG3 - Personalisation of treatment for patients with BTC</b>			
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Anna Saborowski (Germany) &amp; Elene Mariamidze (Georgia)</i>	
11:00 - 11:15	Neoadjuvant therapy: is it time?	Gonzalo Sapisochin (Spain)	
11:15 - 11:30	Biomarker of adjuvant chemotherapy: data from the BILCAP	Chiara Braconi (UK)	
11:30 - 11:45	Insights from the real world data from the international community: strategizing the chemoimmunotherapy	Andrea Casadei-Gardini (Italy)	
11:45 - 12:00	TBD	TBD	
<b>12:00 - 13:00 SESSION 4: WG4 - Patient-centric support management</b>			
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Ana Lleo (Italy) &amp; Mohamed Bouattour (France)</i>	
12:00 - 12:15	The role of nurse in Europe	Gemma Iserte (Spain)	
12:15 - 12:30	Precision-BTC and EORTC: ongoing collaboration	Antonella Cammarota (Italy)	
12:30 - 12:40	Bringing patients' voices to the UK government	Helen Morement (UK)	
12:40 - 12:50	Shining light on hidden cancers: BTC in Europe	Elisabeth Baucells (Spain)	
12:50 - 13:00	TBD	TBD	
<b>13:00-14:30 Lunch</b>			
<b>14:30-15:30 SESSION 5: WG5 - Artificial Intelligence</b>			
	<i>Moderator:</i> 10 minute presentation + 5 minute discussion	<i>Jesper B Andersen (Denmark) &amp; Ghada Nouairia (Sweden)</i>	
14:30 - 14:45	Update on the molecular registry	Colm O'Rourke (Denmark)	
14:45 - 15:00	AI to predict response to Immune Checkpoint Inhibitor in iCCA	Julien Calderaro (France)	
15:00 - 15:15	TBD	Yash Singh (Mayo Clinic, USA)	
15:15 - 15:30	Can AI-based imaging predict ctDNA evolution under treatment?	Angela Ammirabile (Italy)	
<b>15:30-16:30 SESSION 6: WG6 - Drug development using preclinical models</b>			
	<i>Moderators:</i> 10 minute presentation + 5 minute discussion	<i>Marta Afonso (Portugal) &amp; Attila Hunyadi (Hungary)</i>	
15:30 - 15:45	Targeting the stroma (TBD)	Silvia Affo (Spain)	
15:45 - 16:00	Drug discovery with patients derived organoids (TBD)	Daniela Sia (Mount Sinai, USA)	
16:00 - 16:15	Early Neoplastic Transition States as Targets for Precision Prevention	Ed Jarman (UK)	
16:15 - 16:30	TBD	TBD	
16:30 - 16:35	Closing remarks and farewell		